Related by context. All words. (Click for frequent words.) 82 Phase 2a clinical 82 Phase IIa 81 Phase 1b 80 Phase 2b study 80 Phase 2a trial 80 Phase IIb 80 Phase Ib 79 Phase IIa clinical 79 phase 2a 79 Phase 2b 78 phase IIa clinical 78 Phase IIa trial 78 Phase 2b trial 77 phase IIa 77 Phase Ib clinical 77 Phase IIb clinical 76 phase IIb 76 Phase 2b clinical 76 Phase III 75 Phase II 75 Phase III clinical 75 pivotal Phase III 75 Phase 1b trial 74 phase Ib 74 Phase IIb trial 74 Phase 1b clinical 74 Phase 1a 73 Phase Ib study 73 placebo controlled Phase 73 Phase IIb trials 72 Phase Ia 72 pivotal Phase 72 dose escalation Phase 72 GALNS 72 phase IIb clinical 71 Phase Ib II 71 PRX # 71 dose escalation trial 70 Phase IIIb clinical 70 INCB# [001] 70 Phase IIB 70 Phase IIa trials 70 Phase #b/#a 70 Phase 1a clinical 70 dose escalation study 70 multicenter Phase 70 Phase #/#a 70 phase IIb study 70 multiple ascending dose 69 Phase III pivotal 69 phase IIb trial 69 Phase 2b clinical trials 69 NGX# 68 randomized Phase 68 pharmacokinetic PK study 68 confirmatory Phase III 68 pharmacokinetic PK 68 Phase 2a clinical trials 68 Phase 68 Phase III clinical trials 68 Phase III trials 68 Phase IIIb 68 HuMax EGFr 68 alvespimycin 68 confirmatory Phase 3 67 multicenter Phase II 67 R#/MEM # 67 randomized controlled Phase 67 ongoing Phase 1b 67 JAK inhibitor 67 CRLX# 67 bicifadine 67 NP2 Enkephalin 67 registrational 67 CR# vcMMAE 67 Phase IIa clinical trials 67 placebo controlled clinical 67 randomized Phase IIb 67 denufosol 66 dose cohorts 66 cannabinor 66 Phase IIb clinical trials 66 IIa trial 66 BRIM2 66 forodesine 66 microplasmin 66 BRIM3 66 registrational trial 66 Traficet EN 66 KRN# 66 ISIS # 66 phase Ib clinical 66 APEX PD 66 PXD# 66 dose escalation clinical 66 ADVANCE PD 66 IIa clinical trial 66 MEND CABG 65 randomized Phase III 65 dose cohort 65 HGS ETR1 65 oral ridaforolimus 65 Phase III Clinical Trial 65 oral prodrug 65 Phase #/#a trial 65 PEG PAL 65 SUCCEED trial 65 RDEA# 65 Phase #b/#a trial 65 Phase Ib clinical trials 65 Archexin 65 Pivotal Phase III 65 Microplasmin 65 Aurexis 65 II Clinical Trial 65 blinded randomized placebo controlled 65 MERLIN TIMI 65 Cloretazine R VNP#M 65 elotuzumab 65 placebo controlled Phase III 65 dosing cohort 65 multicenter randomized Phase 65 tezampanel 65 Phase IIb Trial 65 Phase III Pivotal 65 Zenvia Phase III 65 placebo controlled 65 ganetespib 65 elagolix 65 Alzhemed TM 65 AeroLEF TM 65 lintuzumab 65 QLT# 65 deforolimus 64 huC# DM4 64 Phase III confirmatory 64 Pivotal Phase 64 FOLOTYN ® 64 PSN# [002] 64 Phase III placebo controlled 64 ocrelizumab 64 Phase 2b Clinical Trial 64 initiate Phase IIb 64 multicenter randomized placebo controlled 64 Phase 2b randomized 64 BCX# 64 PS# [001] 64 INCB# [002] 64 oral formulation 64 single ascending dose 64 Elagolix 64 GLP toxicology studies 64 initiate Phase 64 DDP# 64 HGS# 64 Randomized Phase 64 AEG# 64 Phenoptin 64 clinical trial 64 dose escalation 64 Zerenex 64 Investigational Device Exemption IDE 64 viral kinetic 64 Phase III ALLEGRO 64 preclinical 64 IMA# 64 ProSavin 64 dirucotide 64 evaluating tivozanib 64 dosing cohorts 64 ATL# [001] 64 Mipomersen 64 RG# [001] 64 CRx 64 multicenter Phase III 64 RSD# oral 63 HuMax CD4 63 dyskinesia PD LID 63 EOquin TM 63 Serdaxin 63 preclinical studies 63 Plicera 63 initiate Phase 1b 63 Azedra 63 PEG SN# 63 investigational compound 63 randomized Phase 2b 63 PRECiSE 63 Phase IIa proof 63 NO# [002] 63 AIR CF1 63 Sym# 63 ELACYT 63 Initiate Phase 63 preclinical efficacy 63 OncoVEX GM CSF 63 Exherin TM 63 IND submission 63 riociguat 63 Bicifadine 63 ALKS 63 obatoclax 63 MGCD# [001] 63 selective androgen receptor modulator 63 vidofludimus 63 Phase #b/#a clinical 63 fosbretabulin 63 rNAPc2 63 Triolex 63 RGB # 63 PHX# 63 ozarelix 63 Phase III Clinical Trials 63 pharmacokinetic studies 63 EOquin 63 alvimopan 63 Phase IIb III 63 velafermin 63 PDE4 inhibitor 63 EVIZON 63 virus HCV protease inhibitor 63 TBC# 63 Initiated Phase 63 TMC# [002] 63 histone deacetylase HDAC inhibitor 63 Azixa 63 IDX# 63 tolerability 63 Fx #A 63 pivotal bioequivalence 63 label dose escalation 63 glufosfamide 63 PRT# 62 Vicriviroc 62 ZYBRESTAT 62 davunetide intranasal AL 62 Sapacitabine 62 TACI Ig 62 XmAb# 62 tanespimycin 62 ILLUMINATE 62 Phase Ib IIa 62 trodusquemine 62 Cloretazine ® 62 PDX pralatrexate 62 methylnaltrexone 62 multicenter phase 62 MLN# 62 CRMD# 62 ICA # 62 Ophena TM 62 XL# [003] 62 Phase III Trial 62 Phase 1b clinical trials 62 PD LID 62 teriflunomide 62 investigational humanized monoclonal antibody 62 HuMax CD# 62 investigational pan BCR 62 rilonacept 62 initiate Phase 2b 62 brivaracetam 62 mertansine 62 ascending doses 62 Phase III psoriasis 62 Pivotal Trial 62 Atu# 62 AQ4N 62 axitinib 62 elacytarabine 62 ABSORB trial 62 laquinimod 62 AP# [003] 62 Carfilzomib 62 ALN TTR# 62 Guanilib 62 double blind placebo 62 HspE7 62 neurogenic orthostatic hypotension 62 phase IIb III 62 pradefovir 62 drug pipeline TAFA# 62 Phase IIb Clinical Trial 62 ascending dose 62 ENDEAVOR IV 62 HCV protease inhibitor 62 administered subcutaneously 62 MDV# 62 lomitapide 62 OXi# 62 Chemophase 62 ADX# 62 double blinded placebo 62 orally bioavailable 62 huN# DM1 62 European Sepsis Trial 62 lead Aganocide compound 62 enzastaurin 62 Phase 1b dose escalation 62 IMGN# 62 mGluR5 negative 62 ACAPODENE 62 diabetic neuropathic pain 62 Pimavanserin 62 evaluating RDEA# 62 Zenvia ™ 62 Alocrest 62 Perifosine 62 Phase IIA 62 rALLy clinical trial 61 SPIRIT FIRST 61 unblinding 61 CEQ# 61 ANCHOR trial 61 BAY #-# 61 Bezielle 61 IND enabling 61 LCP AtorFen 61 Ostarine 61 AZILECT ® 61 phase IIIb 61 midstage trials 61 Arikace 61 pharmacodynamic PD 61 MEK inhibitor RDEA# 61 Meets Primary Endpoint 61 mipomersen 61 Parkinson disease levodopa induced 61 Phase III ADT 61 Capesaris 61 randomized multicenter 61 Phase 2b Trial 61 PEG Interferon lambda 61 SAR# [004] 61 eprotirome 61 PRTX 61 MAGE A3 ASCI 61 Phase 2a proof 61 Genz # 61 ADAGIO study 61 TMC# C# 61 multicenter placebo controlled 61 TRO# 61 Gabapentin GR 61 Dacogen injection 61 Tesetaxel 61 CB2 selective receptor agonist 61 liposomal formulation 61 NVA# 61 Hsp# Inhibitor 61 AEGR 61 XL# XL# XL# 61 stated Michelle Berrey 61 CA4P 61 vascular disrupting agent 61 generation NNRTI 61 TG MV 61 Zoraxel 61 cariprazine 61 LibiGel ® 61 Annamycin 61 AACR NCI EORTC 61 PFO migraine 61 AZILECT R 61 DB# [003] 61 evaluating mipomersen 61 multicenter randomized double 61 anticancer compound 61 Safinamide 61 ulimorelin 61 Panzem R NCD 61 Amrubicin 61 Aplidin 61 talactoferrin 61 Ozarelix 61 Atiprimod 61 Tyrima 61 docetaxel Taxotere R 61 Phase 2a Study 61 Ceflatonin 61 metaglidasen 61 Phase III randomized controlled 61 ruxolitinib 61 Combination REOLYSIN R 61 IMPACT DCM 61 GLYX 61 HCV SPRINT 61 Serdaxin ® 61 Tanespimycin 61 Zenvia TM 61 NLX P# 61 OHR/AVR# 61 COSIRA trial 61 HDAC Inhibitor 61 lesinurad 61 LEVADEX 61 OncoGel 61 Androxal TM 61 relapsed refractory multiple myeloma 61 non nucleoside inhibitor 61 novel histone deacetylase 61 randomized placebo controlled 61 RSD# 61 HCV RESPOND 2 61 AMD# [002] 61 compound INCB# 61 VEGF Trap 61 nonclinical studies 61 incyclinide 61 EchoCRT 61 IPL# 61 Ocrelizumab 61 Augment Injectable 61 omacetaxine mepesuccinate 61 celgosivir 61 pharmacokinetic 61 romidepsin 61 AZX# 61 oral FTY# 61 CCR5 antagonist 61 Completes Patient Enrollment 61 carfilzomib 61 Pivotal Study 61 DermaVir Patch 61 label multicenter Phase 61 clinical pharmacology studies 61 ASA# 61 CCR9 antagonist 61 Clinical Trial Results 60 AIR CF2 60 baminercept 60 treatment naive genotype 60 Reolysin 60 IMC A# 60 omega interferon 60 initiated Phase Ib 60 Cannabinor 60 ARIKACE 60 Personalized Immunotherapy 60 torezolid phosphate 60 tgAAC# 60 pharmacokinetics PK 60 masked placebo controlled 60 Zybrestat 60 PSMA ADC 60 oral rivaroxaban 60 fostamatinib 60 ularitide 60 MEK inhibitor 60 XL# SAR# 60 AzaSite Plus 60 ARRY 60 INT# [002] 60 confirmatory clinical 60 acyclovir Lauriad R 60 CIMZIA TM 60 TKB# 60 HGS ETR2 60 Amigal 60 Denufosol 60 Fibrillex TM 60 CUSTOM III 60 ataluren 60 Spheramine 60 ThermoDox R 60 Cotara 60 dextromethorphan quinidine 60 Laquinimod 60 tiapamil 60 Troxatyl 60 TG# [003] 60 VA# [002] 60 CCX# 60 Locteron 60 Urocidin 60 unblinded 60 metastatic hormone refractory 60 Nasulin 60 TPI ASM8 60 refractory CLL 60 nucleotide analog 60 trastuzumab emtansine T DM1 60 Phase III Psoriasis 60 Quinamed 60 AEZS 60 Novolimus 60 teduglutide 60 PRIMO CABG 60 ELND# 60 OMNARIS HFA 60 Veronate 60 lorvotuzumab mertansine 60 LEP ETU 60 budesonide foam 60 thorough QT 60 velafermin belinostat 60 LibiGel Phase III 60 GLPG# 60 Phase 2a Clinical Trial 60 COMFORT II 60 KNS # 60 nab paclitaxel 60 rALLy trial 60 MAP# 60 Dapagliflozin 60 Daclizumab 60 treatment naïve genotype 60 entinostat 60 trastuzumab DM1 T DM1 60 Locteron ® 60 CCR5 mAb 60 Tasimelteon 60 SNT MC# 60 safinamide 60 PreCISe 60 mGluR5 NAM 60 neratinib 60 Aclidinium 60 pertuzumab 60 ANG# 60 immunosuppressive compound 60 SCH # 60 apricitabine 60 Tarvacin TM 60 HQK 60 iSONEP 60 aclidinium 60 bardoxolone 60 Corlux 60 ENDEAVOR III 60 Onrigin 60 randomized controlled multicenter 60 dexpramipexole 60 DR Cysteamine 60 Cethrin R 60 NUVIGIL 60 CAMMS# 60 Factor VIIa 60 cediranib 60 TAXUS ATLAS 60 Diabetic Macular Edema 60 ocular formulation 60 CORT # 60 GetGoal Phase III 60 APTIVUS 60 AVN# [001] 60 PROMACTA 60 multicenter clinical 60 HCD# [002] 60 AVADO 60 Marqibo 60 Darusentan 60 REOLYSIN ® 60 preclinical pharmacokinetic 60 valopicitabine 60 relapsed multiple myeloma 60 GAMMAGARD 60 TH# [003] 60 Apoptone 60 multicentre randomized 60 LUX Lung 60 ofatumumab 60 L BLP# 60 Phase 2a Trial 60 LEVADEX ™ 60 Oglemilast 60 Actilon 60 Luveniq 60 PLX PAD 60 PRX# 60 BAL# [002] 60 BLA submission 60 BrachySil TM 60 receptor tyrosine kinase inhibitor 60 TLK# 60 Cethrin 60 PCK# 60 Proxinium TM 60 MAA submission 60 pseudobulbar affect PBA 60 generation PNP inhibitor 60 ostarine 60 efficacy endpoint 60 PROSTVAC TM 59 ZFP Therapeutic 59 Vitaxin 59 XL# XL# XL# XL# 59 opioid induced bowel dysfunction 59 ZYBRESTAT fosbretabulin 59 dependent kinase inhibitor 59 cystinosis patients 59 octreotide implant 59 Omacetaxine 59 prucalopride 59 TASKi2 59 dose dose escalation 59 sapacitabine 59 varespladib 59 TOLAMBA 59 Aryplase 59 Golimumab 59 cell lymphoma CTCL 59 Viramidine 59 arzoxifene 59 JAK1 59 eculizumab 59 voreloxin 59 LBH# 59 lintuzumab SGN 59 Alpharadin 59 rALLy 59 IIa clinical 59 prospective multicenter randomized 59 dexanabinol 59 cetrorelix 59 label multicenter 59 pomalidomide 59 Lu AA# 59 Enobia 59 DSMB 59 PRE SURGE 59 SPIRIT IV 59 ganaxolone 59 BEMA TM Fentanyl 59 LUMINATE 59 tramiprosate Alzhemed TM 59 ThermoDox ® 59 GSK# [002] 59 Debio 59 DASISION 59 RhuDex ® 59 catheter occlusion 59 tezampanel NGX# 59 alemtuzumab Campath 59 subcutaneous formulation 59 BEMA Buprenorphine 59 eltrombopag 59 analgesic efficacy 59 RLY# 59 leading oral taxane 59 placebo controlled randomized 59 PANVAC VF 59 LymphoStat B TM 59 JAK2 inhibitor 59 Diabetic Macular Edema DME 59 PNP inhibitor 59 initiate Phase Ib 59 Phase 2b Study 59 EndoTAG TM -1 59 Anturol TM 59 ANAVEX #-# [003] 59 aclidinium bromide 59 Tarceva TM 59 CCX# B 59 apricitabine ATC 59 Pirfenidone 59 APPRAISE 59 Cethromycin 59 mGluR2 positive 59 Aflibercept 59 Feasibility Trial 59 Tezampanel 59 active comparator 59 Azedra TM 59 Ophena 59 HER2 positive metastatic breast 59 investigational drug 59 novel nucleoside analog 59 Trofex 59 multicenter 59 ORAL Sync 59 Linaclotide 59 Triapine 59 sNDA submission 59 ORMD 59 MAXY alpha 59 Glufosfamide 59 bendamustine 59 DURATION 59 Xanafide 59 PREOS 59 Restanza 59 Dextofisopam 59 maximally tolerated dose 59 blind randomized placebo 59 Panzem R 59 clinical trials 59 Synavive 59 aflibercept 59 #th Annual Interscience 59 BOLDER II 59 TRIOLEX 59 generation purine nucleoside 59 Thiarabine 59 tolerability profile 59 CUDC 59 blinded placebo controlled 59 OPT CHF 59 Phase III randomized 59 blinatumomab 59 Genasense oblimersen sodium Injection 59 LymphoStat B 59 albiglutide 59 CD NP 59 Pivotal Clinical Trial 59 rindopepimut 59 TEMSO 59 eniluracil 59 intranasal formulation 59 QNEXA 59 IIa trials 59 BNC# 59 picoplatin 59 Completes Patient Enrolment 59 EcoNail 59 Lovaxin C 59 daclizumab 59 Initiates Phase 59 Successfully Completes Phase 59 ToGA 59 nitazoxanide 59 Entereg R 59 MOZOBIL 59 OvaRex ® MAb 59 ProLindac 59 REVLIMID lenalidomide 59 resminostat 59 sunitinib malate 59 RRMS patients 59 GEM OS2 59 ThGRF 59 PI3K/Akt pathway inhibitor 59 IIb clinical trial 59 Phase IIIb study 59 Adlea 59 AMR# 59 Initiates Phase II 59 atacicept 59 Valortim 59 ALN VSP 59 cathepsin K inhibitor 59 unique alkylating agent 59 Hsp# inhibitor 59 COU AA 59 CLORETAZINE TM VNP#M 59 randomized controlled 59 Fodosine 59 IRX 2 59 LY# [003] 59 MIVI III 59 IMC #B 59 Multiple Ascending Dose 59 MEND CABG II 59 allosteric modulator NAM 59 GRN# 59 cancer neuroendocrine tumor 59 GSK# [001] 59 CBLC# 59 TG# [001] 59 ALN RSV# 58 refractory gout 58 R#/MEM 58 Phase 2b monotherapy 58 TOCOSOL Paclitaxel 58 dimebon 58 tamibarotene 58 tolevamer 58 dacetuzumab 58 ospemifene 58 Catena ® 58 Exelixis compounds 58 reslizumab 58 oral deforolimus 58 ENDEAVOR II 58 tesmilifene 58 ATL/TV# 58 secondary efficacy endpoints 58 cetuximab Erbitux 58 oral picoplatin 58 Civacir 58 LibiGel testosterone gel 58 Prostate AdenoCarcinoma Treatment 58 severe hypercholesterolemia 58 Tocosol Paclitaxel 58 BrachySil 58 sitaxsentan 58 ALTU 58 NXL# 58 humanized anti 58 albinterferon alfa 2b 58 Virulizin ® 58 PS# DARA 58 Icatibant 58 Elocalcitol 58 Æterna Zentaris 58 AZX# Phase 58 trial evaluating PRX# 58 IL# PE#QQR 58 pegloticase 58 BIBW 58 randomized discontinuation trial 58 volociximab 58 mg/m2 cohort 58 Hedgehog pathway inhibitor 58 sodium glucose cotransporter 58 REMUNE R 58 telaprevir VX 58 edoxaban 58 generation proteasome inhibitor 58 relapsing remitting multiple sclerosis 58 isavuconazole 58 PrevOnco 58 SYMMETRY trial 58 PROPEL trial 58 ALN TTR 58 ABSORB clinical 58 RhuDex 58 SinuNase TM 58 FOLFOX6 chemotherapy regimen 58 perifosine 58 visilizumab 58 LE SN# 58 pharmacodynamic profile 58 AKT inhibitor 58 Genasense ® oblimersen 58 palifosfamide Zymafos TM 58 GLP1 agonist 58 YONDELIS 58 Nasdaq PGNX today 58 urocortin 2 58 double blinded randomized 58 OLpur TM H2H 58 AMPAKINE CX# 58 seliciclib CYC# 58 Epanova 58 crofelemer 58 CYT# potent vascular disrupting 58 Testosterone MDTS ® 58 Empatic 58 orally administered inhibitor 58 midstage clinical trials 58 PF # [001] 58 Inhalation Solution 58 VICTOR E1 58 ILUVIEN ® 58 HCV NS5B polymerase 58 VNP#M 58 Presents Positive 58 ONCONASE R 58 Efficacy Results 58 assessing T DM1 58 farletuzumab 58 SABCS 58 investigational oral 58 Ceflatonin R 58 OMP #M# 58 Achieves Primary Endpoint 58 rFIXFc 58 glucokinase activator 58 Phase 2b kidney transplant 58 Vernakalant 58 ACTEMRA TM 58 Pivotal Trials 58 Relovair 58 Diamyd ® 58 GOUT 58 Hyphanox 58 AVE# 58 CIMZIA ™ 58 metastatic castrate resistant 58 tasimelteon 58 CYT# 58 fidaxomicin Phase 3 58 ACCORD COPD 58 safety tolerability 58 Pazopanib 58 lucinactant 58 docetaxel chemotherapy 58 transcriptase inhibitor NNRTI 58 otelixizumab 58 PLK1 SNALP 58 PMX # 58 Hedgehog antagonist 58 Orazol 58 PA# [002] 58 FTY# fingolimod 58 GRN#L 58 lumiliximab 58 miconazole Lauriad ® 58 symptomatic BPH 58 GATTEX TM 58 Oral NKTR 58 registrational studies 58 DU #b 58 Cetrorelix 58 initiated Phase 1b 58 TELINTRA 58 nonrandomized 58 oral Xeloda 58 UPLYSO 58 CD# CEA 58 OvaRex R 58 LymphoStat B belimumab 58 Prodarsan 58 prospective randomized controlled 58 dose escalation phase 58 randomized double 58 oral taxane 58 interferon gamma 1b 58 Nasdaq VRTX 58 ACV1 58 PEARL SC 58 Opexa 58 mapatumumab 58 CHAMPION PCI 58 clinical trials Multikine 58 Imprime PGG 58 Shigamabs ® 58 inhaled liposomal ciprofloxacin 58 Clolar ® 58 Presents Preclinical 58 Board DSMB 58 Dual Opioid 58 prospective multicenter 58 pralatrexate injection 58 Phase III Trials 58 eosinophilic asthma 58 PEGylated interferon beta 1a 58 Benlysta belimumab 58 Cloretazine 58 Ofatumumab 58 belinostat 58 zalutumumab 58 APOPTONE 58 APEX AMI trial 58 TELCYTA 58 REVIVE Diabetes 58 amrubicin 58 CDP# 58 Biopharmaceuticals AG 58 next generation URAT1 58 Kamada AAT 58 ORENCIA ® 58 Cinquil 58 Genasense ® 58 IMPACT DCM clinical 58 bosentan 58 Allovectin 7 R 58 Phase IIa Clinical Trial 58 HuLuc# 58 REG1 Anticoagulation System 58 null responder HCV 58 GV# [001] 58 Rezular 58 Alfimeprase 58 Randomized Phase II 58 Vilazodone 58 ARDIS 58 severe gastroparesis 57 talabostat 57 HepeX B TM 57 Ventavis 57 plus Copegus R 57 IIa clinical trials 57 zanolimumab 57 acute peripheral arterial 57 dacetuzumab SGN 57 sulodexide 57 oral calcitonin 57 CINQUIL 57 CG# [003] 57 inhaled formulation 57 LCP Tacro 57 CTAP# Capsules 57 ALD# 57 radezolid 57 USL# 57 acute PAO 57 Cimzia ® certolizumab pegol 57 T Pred 57 Reverset 57 Romidepsin 57 eliglustat tartrate 57 Huntexil 57 oral sapacitabine 57 Tamibarotene 57 RezularTM 57 metastatic castration resistant 57 Symadex 57 radiation sensitizer 57 MIST II 57 afamelanotide 57 ITAX 57 EDEMA3 57 Solulin 57 Nasdaq RDEA 57 oxymorphone ER 57 Forodesine HCl 57 Phase III VISTA